These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 5162168)

  • 1. The influence of Clofibrat on plasma lipid levels.
    Szostak WB; Cybulska B; Ruzyllo E
    Mater Med Pol; 1971; 3(4):12-4. PubMed ID: 5162168
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of long-term administration of clofibrate on the composition of blood lipids in patients with atherosclerosis.
    Poleszak J; Korolko A
    Pol Med J; 1972; 11(2):250-6. PubMed ID: 5071512
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapeutic effect of pyridylcarbinolic ester of clofibric acid on the changes of the lipid and fibrinolytic picture in arteriosclerotic patients].
    Rugginenti
    Minerva Med; 1974 May; 65(35):1906-16. PubMed ID: 4601840
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative studies on the influence of Provasan, Complamine, Sadamine, A-100 and Clofibrat on the behaviour of some lipid fractions of plasma in experimental animals.
    Sulowska Z
    Mater Med Pol; 1974; 6(2):102-6. PubMed ID: 4431240
    [No Abstract]   [Full Text] [Related]  

  • 5. [Effect of long-term administration of clofibrate on the composition of blood lipids in atherosclerotic patients].
    Poleszak J; Korolko A
    Pol Tyg Lek; 1971 Jul; 26(29):1106-9. PubMed ID: 5098907
    [No Abstract]   [Full Text] [Related]  

  • 6. [Clinical evaluation of the therapeutic activity of the -pyridyl-carbinol ester of clofibric acid].
    Silingardi V; Renzi R; Mora A; Di Prisco AU
    Minerva Med; 1973 Mar; 64(16):751-69. PubMed ID: 4704721
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effect of clofibrate on serum lipid pattern in patients with arteriosclerosis].
    Markiewicz K; Walasek L; Pelka W; Lutz W
    Pol Tyg Lek; 1973 Jul; 28(30):1144-7. PubMed ID: 4732710
    [No Abstract]   [Full Text] [Related]  

  • 8. [Current trends in the therapy of arteriosclerotic disease].
    Toscano S
    G Clin Med; 1974 Jan; 55(1):27-39. PubMed ID: 4369524
    [No Abstract]   [Full Text] [Related]  

  • 9. Clofibrate and niacin in coronary heart disease.
    JAMA; 1975 Jan; 231(4):360-81. PubMed ID: 1088963
    [No Abstract]   [Full Text] [Related]  

  • 10. Study of serum lipid fractions as related to blood coagulation, fibrinolysis and platelet aggregation in cholesterol fed rabbits and in arteriosclerotic patients given clofibrate.
    Baldoni E; Egge H; Cuttin S; Murawski U; Gibelli A; Giarola P
    Farmaco Sci; 1973 Sep; 28(9):713-21. PubMed ID: 4749857
    [No Abstract]   [Full Text] [Related]  

  • 11. Platelet stickiness and serum cholesterol levels after myocardial infarction treated with clofibrate and heparine.
    Kusá O
    Acta Univ Carol Med Monogr; 1972; 53():413-6. PubMed ID: 4670747
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clofibrate and phosphate metabolism].
    Michailov ML
    Cor Vasa; 1984; 26(4):309-16. PubMed ID: 6488804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of clofibrate, Isopharm, on fat tolerance in atherosclerotic patients].
    Passowicz L
    Pol Tyg Lek; 1972 Jul; 27(30):1163-6. PubMed ID: 5073024
    [No Abstract]   [Full Text] [Related]  

  • 14. [Influence of the change in the dose of Clofibrate Spofa and interruption of treatment on the lipid level of blood serum in persons with hyperlipemia].
    Cagánová A; Cagán S
    Bratisl Lek Listy; 1972 Jul; 58(1):66-78. PubMed ID: 5077942
    [No Abstract]   [Full Text] [Related]  

  • 15. [Arteriosclerosis--the mutual contribution of the arterial wall cells and serum lipids].
    Bar-On H; Stein Y
    Harefuah; 1972 Mar; 82(5):221-3. PubMed ID: 4559492
    [No Abstract]   [Full Text] [Related]  

  • 16. [Phenformin treatment of arteriosclerotic patients: changes induced in the plasma lipid picture. Preliminary note].
    Negri AU; Matteoli E; Zaini GF; Riva D
    Minerva Med; 1971 Nov; 62(89):4405-12. PubMed ID: 5162252
    [No Abstract]   [Full Text] [Related]  

  • 17. [Changes in the spectrum of serum lipids following 3 months administration of clofibrate Spofa].
    Cagánova A; Cagan S
    Cesk Farm; 1971 Nov; 20(9):341-6. PubMed ID: 5136172
    [No Abstract]   [Full Text] [Related]  

  • 18. [Therapeutic use of miscleron in patients with diabetes mellitus and cardiovascular disorders].
    Spesivtseva VG; Kakhnovskiĭ IM; Dorokhova AS; Al'bert LB
    Sov Med; 1973 Dec; 36(12):26-31. PubMed ID: 4779361
    [No Abstract]   [Full Text] [Related]  

  • 19. Fasting and nonfasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction.
    Langsted A; Freiberg JJ; Nordestgaard BG
    Circulation; 2008 Nov; 118(20):2047-56. PubMed ID: 18955664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.
    Li JZ; Chen ML; Wang S; Dong J; Zeng P; Hou LW
    Chin Med J (Engl); 2004 Feb; 117(2):163-7. PubMed ID: 14975195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.